Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LT-103
- Development stage
- Preclinical
- Lead developer
- lncTAC Bio
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Topical, Transdermal
01
Overview
LT-103 is a preclinical-stage, long non-coding RNA (lncRNA)-based therapeutic being developed by lncTAC for the treatment of melasma. The drug is designed to be delivered topically via the company's proprietary transdermal delivery platform, which enables the delivery of small nucleic acids into the skin.
Beyond the preview
Go deeper on LT-103.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LT-103.